5 Stocks to Buy Now According to David Einhorn’s Greenlight Capital

2. LivaNova PLC (NASDAQ:LIVN)

Greenlight Capital’s Stake Value: $36,004,000 

Percentage of Greenlight Capital’s 13F Portfolio: 2.28%

Number of Hedge Fund Holders: 33

LivaNova PLC (NASDAQ:LIVN) is a medical device company that designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. As of May 5, Piper Sandler analyst Adam Maeder has a $99 price target and a buy-side Overweight rating on LivaNova PLC (NASDAQ:LIVN).

This July, Piper Sandler analysts reported that they see the medical technology sector approaching a trough, with a further 10% to 15% downside expected in shares. The analysts noted that they see persistent headwinds in the sector. However, they are recommending med-tech stocks like LivaNova PLC (NASDAQ:LIVN) to investors as a result of strong fundamentals, improving case volumes, and strong balance sheets.

In the first quarter of 2022, Greenlight Capital raised its stakes in LivaNova PLC (NASDAQ:LIVN) by 30%, bringing them to $36 million. The investment covers 2.28% of David Einhorn’s 13F portfolio.

At the close of Q1 2022, 33 hedge funds disclosed ownership of stakes in LivaNova PLC (NASDAQ:LIVN). The collective stakes of these hedge funds amounted to $1.17 billion. This is compared to 31 hedge funds in Q4 2021 with stakes worth $1.28 billion.